COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Garnica, Marcia; Crusoe, Edvan De Queiroz; Ribeiro, Glaciano; Bittencourt, Rosane; Magalhães, Roberto José Pessoa; Zanella, Karla Richter; Hallack Neto, Abrahão Elias; Lima, Juliana Souza; Solo, Caroline Bonamin; Souza, Emmanuella Graciott; Fernandes, Andre Magalhaes; Maiolino, Angelo; Hungria, Vania

doi:10.1016/j.htct.2023.08.002

Cited by 2 publications

(2 citation statements)

References 23 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings on the anti-CD38 antibody daratumumab in relation to COVID-19 severity and complications have been mixed [ 61 , 64 ]. Proteasome inhibitors and corticosteroids have been associated with an increased risk of severe COVID-19 outcomes, including ICU admissions and mechanical ventilation [ 45 , 65 , 66 ]. On the other hand, stem cell transplant within a year of infection does not appear to increase the risk of severe COVID-19 outcomes and, in some cases, shows more favorable outcomes [ 36 , 45 , 58 , 67 , 68 ].…”

Section: Impact Of Covid-19 On Different Types Of Hmmentioning

confidence: 99%

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Ng,

Alata,

Nguyen

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient.

show abstract

Section: Impact Of Covid-19 On Different Types Of Hmmentioning

confidence: 99%

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Ng,

Alata,

Nguyen

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…et al e Viana, M.A. et al published in this edition of "Hematology, Transfusion and Cell Therapy”, discuss relevant hematological diseases under the Brazilian perspective 8 , 9 , 10 , 11 .…”

mentioning

confidence: 99%

Are we securing our future workforce of physician-scientists in hematology?

Facco,

De Paula

2024

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Cited by 2 publications

References 23 publications

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Are we securing our future workforce of physician-scientists in hematology?

Contact Info

Product

Resources

About